Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Abemaciclib in Locally Advanced Soft Tissue Sarcoma: NCT06498648 Clinical Landscape Report 2026
9 min read
Abemaciclib in Locally Advanced Soft Tissue Sarcoma: NCT06498648 Clinical Landscape Report 2026
16 October 2026
NCT06498648 clinical landscape for Locally Advanced Soft Tissue Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white…
Read →
B7-H3CART(Stanford University) in Relapsed Solid Neoplasm: NCT06500819 Clinical Landscape Report 2026
9 min read
B7-H3CART(Stanford University) in Relapsed Solid Neoplasm: NCT06500819 Clinical Landscape Report 2026
16 October 2026
NCT06500819 clinical landscape for Relapsed Solid Neoplasm: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Penpulimab in Melanoma: NCT06500091 Clinical Landscape Report 2026
9 min read
Penpulimab in Melanoma: NCT06500091 Clinical Landscape Report 2026
16 October 2026
NCT06500091 clinical landscape for Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Radspherin in Endometrioid intraepithelial neoplasia: NCT06504147 Clinical Landscape Report 2026
9 min read
Radspherin in Endometrioid intraepithelial neoplasia: NCT06504147 Clinical Landscape Report 2026
16 October 2026
NCT06504147 clinical landscape for Endometrioid intraepithelial neoplasia: endpoints, sponsor, phase, geography, readouts, asset context and development whit…
Read →
Monalizumab in Non-Muscle Invasive Bladder Urothelial Carcinoma: NCT06503614 Clinical Landscape Report 2026
9 min read
Monalizumab in Non-Muscle Invasive Bladder Urothelial Carcinoma: NCT06503614 Clinical Landscape Report 2026
16 October 2026
NCT06503614 clinical landscape for Non-Muscle Invasive Bladder Urothelial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and develo…
Read →
Anti-BCMA and CD19 CART(Anhui Provincial Hospital) in Autoimmune Diseases: NCT06503224 Clinical Landscape Report 2026
9 min read
Anti-BCMA and CD19 CART(Anhui Provincial Hospital) in Autoimmune Diseases: NCT06503224 Clinical Landscape Report 2026
16 October 2026
NCT06503224 clinical landscape for Autoimmune Diseases: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Fludeoxyglucose F-18 in Hepatocellular Carcinoma: NCT06503146 Clinical Landscape Report 2026
9 min read
Fludeoxyglucose F-18 in Hepatocellular Carcinoma: NCT06503146 Clinical Landscape Report 2026
16 October 2026
NCT06503146 clinical landscape for Hepatocellular Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Iron Dextran in Melanoma: NCT06508827 Clinical Landscape Report 2026
9 min read
Iron Dextran in Melanoma: NCT06508827 Clinical Landscape Report 2026
16 October 2026
NCT06508827 clinical landscape for Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
KLS-1 in Locally Advanced Malignant Solid Neoplasm: NCT06506643 Clinical Landscape Report 2026
9 min read
KLS-1 in Locally Advanced Malignant Solid Neoplasm: NCT06506643 Clinical Landscape Report 2026
16 October 2026
NCT06506643 clinical landscape for Locally Advanced Malignant Solid Neoplasm: endpoints, sponsor, phase, geography, readouts, asset context and development w…
Read →
Pembrolizumab in Recurrent Endometrial Cancer: NCT06502743 Clinical Landscape Report 2026
9 min read
Pembrolizumab in Recurrent Endometrial Cancer: NCT06502743 Clinical Landscape Report 2026
16 October 2026
NCT06502743 clinical landscape for Recurrent Endometrial Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Zorpocabtagene autoleucel in Acute Lymphoblastic Leukemia: NCT06508775 Clinical Landscape Report 2026
9 min read
Zorpocabtagene autoleucel in Acute Lymphoblastic Leukemia: NCT06508775 Clinical Landscape Report 2026
16 October 2026
NCT06508775 clinical landscape for Acute Lymphoblastic Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Nadofaragene firadenovec-vncg in Non-Muscle Invasive Bladder Neoplasms: NCT06510374 Clinical Landscape Report 2026
9 min read
Nadofaragene firadenovec-vncg in Non-Muscle Invasive Bladder Neoplasms: NCT06510374 Clinical Landscape Report 2026
16 October 2026
NCT06510374 clinical landscape for Non-Muscle Invasive Bladder Neoplasms: endpoints, sponsor, phase, geography, readouts, asset context and development white…
Read →